In the patients with HER2+ early breast cancer (EBC), HR+ patients perform a better 5-years disease-free survival (DFS) than HR- patients; however, the recurrence risk may persist longer in HR+ patients, finally resulting in a similar long-term outcome compared to the HR- patients (8). Here, ERBB2 is linked to breast carcinoma.